Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"RadioMedix","sponsor":"Plus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Portland Investment Counsel Inc.","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Platform and Diagnostic Companion Radiopharmaceuticals to Address Unmet Needs in Oncology; Michael Lee-Chin Appointed to The Board of The Company","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Fusion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharmaceuticals Inc.","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"RadioMedix","sponsor":"Oranomed","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RadioMedix and Orano Med Receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by RadioMedix

    Menu

    RadioMedix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              RadioMedix

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RadioMedix and Orano Med Receive FDA Breakthrough Therapy Designation for AlphaMedixTM in Gastroenteropancreatic Neuroendocrine Tumors

              Details:

              AlphaMedix (212Pb-DOTAMTATE) is a targeted alpha therapy, being developed for treatment of adults with unresectable/metastatic, progressive somatostatin receptor expressing gastroenteropancreatic neuroendocrine tumors who are naïve to peptide receptor radionuclide therapy.

              Lead Product(s): Alphamedix

              Therapeutic Area: Oncology Product Name: AlphaMedix

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Oranomed

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RadioMedix

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RadioMedix and Orano Med Complete Patient Enrolment in Phase II Trial of Targeted Alpha-Emitter AlphaMedix in Neuroendocrine Cancers

              Details:

              AlphaMedixTM is a radiolabeled SSTR-targeting therapeutic investigational drug for the treatment of NETs patients. The product consists of SSTR-targeting peptide complex radiolabeled with 212Pb dotamtate that serves as an in vivo generator of alpha-emitting particles.

              Lead Product(s): Alphamedix

              Therapeutic Area: Oncology Product Name: AlphaMedix

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Oranomed

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 16, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RadioMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer, by Fusion Pharm...

              Details:

              Through the acquisition of Phase 2 program evaluating 225Ac-PSMA I&T, a small molecule targeting prostate specific membrane antigen ("PSMA") expressed on prostate cancers, strengthens the pipeline of innovative targeted alpha therapies.

              Lead Product(s): Ac225-PSMA

              Therapeutic Area: Oncology Product Name: Ac225-PSMA

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Fusion Pharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition February 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RadioMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              RadioMedix Announces a $40 Million Series A Financing for The Advancement of Novel Targeted Alpha Therapy Platform and Diagnostic Companion Radiopharmaceuticals to Address ...

              Details:

              The proceeds of the financing will be applied to developing RadioMedix’s flagship radiopharmaceutical AlphaMedix™, a lead-212 (Pb212) labelled somatostatin analogue TAT agent for the treatment of metastatic or inoperable somatostatin expressing neuroendocrine tumors.

              Lead Product(s): Alphamedix

              Therapeutic Area: Oncology Product Name: AlphaMedix

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Portland Investment Counsel Inc.

              Deal Size: $40.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing October 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              RadioMedix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug

              Details:

              This strategic partnership substantially supports efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).

              Lead Product(s): Rhenium-186 NanoLiposome

              Therapeutic Area: Oncology Product Name: 186RNL

              Highest Development Status: Phase I/ Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Plus Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY